VJHemOnc is committed to improving our service to you

EHA 2019 | Major AML treatment landscape changes

VJHemOnc is committed to improving our service to you

Christoph Röllig

Christoph Röllig, MD, Dresden University of Technology, Dresden, Germany, describes the breaking down of diagnostic and treatment algorithms to aid in the selection of front-line de novo acute myeloid leukemia (AML) therapy. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter